GlycoEra Company
GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases. It leverages its proprietary CustomGlycan platform to design biologics that selectively target and degrade disease-causing proteins, such as autoantibodies, without broadly suppressing the immune system. The company's lead program, GE8820, is engineered to degrade pathogenic IgG4 autoantibodies with high specificity and efficiency, addressing conditions like pemphigus, muscle-specific kinase (MuSK) myasthenia gravis, primary membranous nephropathy, and autoimmune encephalitis. This approach offers the potential for earlier intervention and improved patient outcomes compared to existing therapies.
Employee Number:
11-50
Headquarters:
Wädenswil, Zurich, Switzerland, Europe
Founded Date:
2020-01-01
Industry:
Drug Discovery & Development
Super Industry:
Biopharma & Life Science Tools
Phone Number:
+41 44 733 8575
Investors:
Agent Capital, Catalio Capital Management, Novo Holdings, Sixty Degree Capital, Sofinnova Partners
Ipo Status:
private
City:
Wädenswil
Region:
Zurich
Country:
Switzerland
Founders:
Amir Faridmoayer, Dominique N. Sirena, Veronica Gambillara Fonck